A Randomized, Multicenter, Phase I/IIa Clinical Study to Evaluate the Tolerability, Safety, Efficacy, Pharmacokinetics and Immunogenicity of GB221 for Injection for the Treatment of HER2-positive Breast Cancer Patients

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary) ; Capecitabine
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Genor Biopharma

Most Recent Events

02 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
02 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
18 May 2020 Planned End Date changed from 1 Apr 2020 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight